TheraRadar
← Back
Data updated: Jun 28, 2026

AIR LIQUIDE CANADA INC

Pharma
Pharmaceuticals

AIR LIQUIDE CANADA INC is a pharmaceutical company with 2 FDA-approved products.

2020
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

AIR LIQUIDE CANADA INC's Key Drugs

AIR LIQUIDE CANADA INC's core commercial portfolio centers on OXYGEN, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.

OXYGEN, USP
Respiratory
Approved 2013
NITROGEN, NF
Other
Approved 2013

AIR LIQUIDE CANADA INC's Recent FDA Approvals

New NDA/BLA approvals for AIR LIQUIDE CANADA INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AIR LIQUIDE CANADA INC's Therapeutic Areas

Disease areas where AIR LIQUIDE CANADA INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIR LIQUIDE CANADA INC Pipeline Snapshot

Active clinical trials for AIR LIQUIDE CANADA INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OXYGEN, USP leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling